Our Emerging Pipeline of Small Molecules
Our lead compound, JBZ-001, is our next-generation DHODH inhibitor that has demonstrated strong preclinical proof-of-concept (PoC) data in many cancer models, confirming its robust anti-cancer activity (explore preclinical data here). These promising results have paved the way for its progression into early-stage clinical development.
JBZ-001 (Advanced Solid and NHL)
Single-Agent
We have recently begun a phase 1, open-label, dose-escalation and expansion, first-in-human trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JBZ-001, in patients with advanced solid and Non-Hodgkin’s Lymphoma.
JBZ-001 (r/r Multiple Myeloma)
+ CD38-targeting antibodies
Our strong preclinical data suggests that JBZ-001 will potently synergize with CD38-targeting antibodies. We expect to raise funds to initiate a phase 1 clinical trial in r/r MM by Q2 2025.
DISCOVERY
PRECLINICAL
EARLY-STAGE CLINICAL DEVELOPMENT
EARLY-STAGE CLINICAL DEVELOPMENT
JBZ-001 (advanced solid tumors)
+ CD47-targeting antibodies
Our strong preclinical data suggests that JBZ-001 will potently synergize with CD47-targeting antibodies. We expect to raise funds to initiate a phase 1 clinical trial in advanced solid tumors by Q2 2025.
DISCOVERY
PRECLINICAL
EARLY-STAGE CLINICAL DEVELOPMENT
EARLY-STAGE CLINICAL DEVELOPMENT
Our Product Roadmap
Explore JBZ-001’s journey from discovery to clinical trials. This timeline highlights our key regulatory milestones achieved and anticipated, showcasing our commitment to advancing this innovative DHODH inhibitor for cancer treatment.